Investors Purchase High Volume of Sarepta Therapeutic Put Options (SRPT)
Sarepta Therapeutic (NASDAQ:SRPT) was the target of some unusual options trading activity on Friday. Traders purchased 27,829 put options on the stock, AR Network reports. This represents an increase of 924% compared to the average daily volume of 2,718 put options.
In other Sarepta Therapeutic news, Director M Kathleen Behrens purchased 6,500 shares of the stock on the open market in a transaction that occurred on Monday, September 16th. The stock was purchased at an average price of $37.04 per share, with a total value of $240,760.00. Following the transaction, the director now directly owns 44,166 shares in the company, valued at approximately $1,635,909. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Needham & Company reiterated a “positive” rating on shares of Sarepta Therapeutic (NASDAQ:SRPT) in a research note to investors on Monday. Separately, analysts at Piper Jaffray Cos. upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “neutral” rating to an “overweight” rating in a research note to investors on Friday. Finally, analysts at Deutsche Bank upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “hold” rating to a “buy” rating in a research note to investors on Friday. They now have a $71.00 price target on the stock, up previously from $45.00.
Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Sarepta Therapeutic presently has a consensus rating of “Buy” and a consensus target price of $52.43.
Sarepta Therapeutic (NASDAQ:SRPT) opened at 43.30 on Monday. Sarepta Therapeutic has a 1-year low of $13.99 and a 1-year high of $47.35. The stock’s 50-day moving average is $35.37 and its 200-day moving average is $36.14. The company’s market cap is $1.452 billion.
Sarepta Therapeutic (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.67) by $0.21. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.08 million. Sarepta Therapeutic’s revenue was down 73.2% compared to the same quarter last year. Analysts expect that Sarepta Therapeutic will post $-3.24 EPS for the current fiscal year.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.